ZDHHC3 and metabolic dysfunction-associated steatohepatitis: Irhom2 (C448A) and Zdhhc3 corestoration in hepatocytes did not upregulate LW/BW ratio, increase dysregulated glucose metabolism, lipid deposition contents, serum pro‐inflammatory cytokines production and liver enzymes levels, compared to Irhom2 (WT) and Zdhhc3 co‐injected mice during NASH development, suggesting that Irhom2 (C448) was indeed the primary site of palmitoylation modification in Mus musculus, and Irhom2 with this mutated site directly lost its promoting effect on NASH progression and functioned as a catalytic substrate of Zdhhc3 (Figure S12b–j, Supporting Information).